KDR and neoplasm: Indeed, sorafenib inhibits the phosphorylation of various targets present in the signaling pathways of both tumor cells (i.e., CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumor-endothelial cells (i.e., CRAF, VEGFR-2, VEGFR-3, and PDGFR-β) [39,40,41].